RenovoRx Inc (RNXT)

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity
MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used chemotherapy.

As RenovoRx continues to advance its therapeutic pipeline, it is simultaneously expanding commercialization of RenovoCath as a stand-alone device, driving adoption at leading cancer centers and building strategic and clinical collaborations that can support future revenue growth and broader platform use. RenovoCath, a patented FDA-cleared device, employs a dual-balloon infusion catheter for targeted delivery of therapeutic agents directly near a tumor.

This is RenovoRx’s second ODD in pancreatic cancer, and third designation in total, reflecting the Company’s differentiated approach to targeted intra-arterial drug-delivery using RenovoCath. RenovoRx previously received ODD for intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in locally advanced pancreatic cancer (LAPC) and bile duct cancer. This designation for oxaliplatin, a platinum-based chemotherapy widely used in pancreatic cancer treatment, further supports the versatility of RenovoRx's novel approach to delivering multiple therapeutic agents directly near the tumor site.

ODD carries meaningful regulatory and financial benefits, including:

Seven years of market exclusivity: Upon FDA approval of the designated indication (in this case, intra-arterial oxaliplatin for pancreatic cancer via RenovoCath), RenovoRx would be entitled to seven years of exclusive marketing rights, during which the FDA cannot approve the same drug for the same orphan indication by another sponsor.
Federal tax credit: A 25% tax credit on qualified clinical research expenses incurred in connection with the designated drug.
FDA application fee waiver: A waiver of the FDA application filing fee, which currently exceeds several million dollars for applications requiring clinical data.
Eligibility for orphan product development grants: Access to grant funding from the FDA’s Orphan Products Development grants program to support clinical development.
“Receiving a third ODD from the FDA is an important milestone as it provides additional validation of our strategy to build a multi-agent, targeted, drug-delivery oncology pipeline enabled by our patented RenovoCath device,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “Our differentiated technology is designed to deliver therapeutic agents intra-arterially across the arterial wall directly near the tumor site, with potential applications across multiple therapeutic agents and multiple cancer types. The FDA’s ODD of oxaliplatin not only expands our pipeline, but also provides valuable regulatory incentives, including seven years of potential market exclusivity and a waiver of FDA application fees that can total several million dollars. While we are laser focused on finishing our current Phase III clinical trial and advancing commercialization of RenovoCath as a standalone device, we remain committed to advancing our platform and exploring the full potential of targeted oxaliplatin delivery in patients diagnosed with difficult-to-treat cancers.”

Pancreatic cancer remains one of the deadliest malignancies, with an estimated 67,530 new cases and more than 52,740 deaths expected in the United States in 2026, according to the American Cancer Society.[1] Despite advances in oncology, the disease is often diagnosed at a late stage in the majority of patients, and the five-year survival rate remains approximately 13%1, underscoring the profound unmet, yet urgent, medical need for new therapeutic approaches.

Oxaliplatin is a key component of FOLFIRINOX, one of the most widely used chemotherapy regimens for patients with advanced pancreatic cancer. RenovoRx is advancing a differentiated approach by delivering oxaliplatin directly near the tumor site using its RenovoCath device.

“This designation for intra-arterial oxaliplatin highlights the breadth of what RenovoCath may offer to pancreatic cancer patients,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “Intra-arterial oxaliplatin may broaden the range of pancreatic cancer targets beyond LAPC that could benefit from localized drug-delivery with RenovoCath."

This ODD for intra-arterial oxaliplatin is separate from and in addition to RenovoRx’s existing ODD for IAG in LAPC and bile duct cancer, which also carries seven years of market exclusivity upon NDA approval by the FDA. RenovoRx's TIGeR-PaC Phase III clinical trial evaluating IAG in LAPC continues to advance, with the Company anticipating notification of enrollment closure in June 2026 and final data readout in mid to late 2027.

About RenovoCathBased on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

1https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html

RenovoRx (RNXT) price target increased by 10.66% to $6.88

Story by George Maybach • 2w

RNXT has been revised to $6.88 / share. This is an increase of 10.66% from the prior estimate of $6.22 dated February 1, 2026.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $3.03 to a high of $13.65 / share. The average price target represents an increase of 663.39% from the latest reported closing price of $0.90 / share.

What is the Fund Sentiment?
There are 37 funds or institutions reporting positions in RenovoRx. This is an decrease of 2 owner(s) or 5.13% in the last quarter. Average portfolio weight of all funds dedicated to RNXT is 0.02%, an increase of 24.28%. Total shares owned by institutions decreased in the last three months by 19.94% to 5,940K shares.

What are Other Shareholders Doing?
AIGH Capital Management holds 2,834K shares representing 7.73% ownership of the company. In its prior filing, the firm reported owning 2,615K shares , representing an increase of 7.72%. The firm decreased its portfolio allocation in RNXT by 25.11% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,057K shares representing 2.88% ownership of the company. No change in the last quarter.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 432K shares representing 1.18% ownership of the company. In its prior filing, the firm reported owning 268K shares , representing an increase of 37.95%. The firm increased its portfolio allocation in RNXT by 93.16% over the last quarter.

Geode Capital Management holds 371K shares representing 1.01% ownership of the company. In its prior filing, the firm reported owning 371K shares , representing a decrease of 0.02%. The firm decreased its portfolio allocation in RNXT by 65.90% over the last quarter.

Wealthspire Advisors holds 253K shares representing 0.69% ownership of the company.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Link article

$RNXT 💹

$668B Oncology Surge: 5 Platforms Cracking the Code on GI TumorsJanuary 30, 2026 10:19 AM
PR Newswire (US)

Issued on behalf of Oncolytics Biotech Inc.USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers where clinical velocity is finally shattering historical benchmarks. With the FDA's 2026 framework explicitly prioritizing accelerated pathways for platforms showing superior objective response rates and durability[2], a select group of innovators is unlocking the immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ: ONCY), Pfizer (NYSE: PFE), Verastem Oncology (NASDAQ: VSTM), Perspective Therapeutics (NYSE-A: CATX), and RenovoRx (NASDAQ: RNXT) directly at the intersection of pivotal execution and breakthrough immunotherapy.  As the market charges toward a staggering $668 billion valuation by 2034, capital is rotating aggressively toward execution-ready platforms over speculative assets[3]. Fresh FDA guidance issued in December 2025 and January 2026 signals a decisive new era emphasizing overall survival and robust clinical benefit[4]. This shift creates asymmetric upside for companies demonstrating disciplined execution in high-stakes battlegrounds like colorectal, pancreatic, and anal cancers, where targeted immunotherapies are establishing entirely new treatment paradigms.Oncolytics Biotech Inc. (NASDAQ: ONCY) is building out its leadership team as it moves its cancer treatment pelareorep through late-stage clinical trials targeting several gastrointestinal cancers.The company recently announced two key hires: John McAdory as Executive Vice President of Strategy and Operations, and Yujun Wu as Vice President, Head of Biostatistics. McAdory comes from CG Oncology, where he ran late-stage clinical trials for oncolytic virus therapies (cancer-fighting viruses, similar to pelareorep). Wu joins from Morphic Therapeutic, where he led the statistics department through the company's sale to Eli Lilly, and previously designed multiple Phase 3 oncology trials at Takeda. Both bring the specific expertise needed to execute the complex, multi-country registration trials that determine whether a drug gets FDA approval."John's background running complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics' next phase of execution," said Jared Kelly, CEO of Oncolytics Biotech. "As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment."These hires complete a significant management upgrade. Kelly and Chief Business Officer Andrew Aromando both joined from Ambrx Biopharma, which sold to Johnson & Johnson for $2 billion in 2024. The company also added three leading cancer specialists from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center to its gastrointestinal tumor scientific advisory board.The clinical data driving this expansion looks compelling. In colorectal cancer, pelareorep combined with chemotherapy and a vascular endothelial growth factor (VEGF) inhibitor achieved a 33% response rate in patients with KRAS mutations (a genetic marker found in about 40% of colorectal cancers). That's three times better than the 6-11% response rate chemotherapy and a VEGF inhibitor typically achieves in these patients. Response rate measures the percentage of patients whose tumors shrink significantly or disappear entirely.In anal cancer, where treatment options are extremely limited after first-line therapy fails, pelareorep is showing even stronger results. Third-line patients (those who've already failed two prior treatments) saw a 29% response rate with responses lasting around 17 months. That nearly triples the historical benchmarks in a setting where no FDA-approved treatments currently exist.In second-line patients, the 30% response rate more than doubled the 13.8% benchmark for the only FDA-approved immunotherapy available, with responses lasting 15.5 months versus 9.5 months for standard treatment.Oncolytics has also secured FDA agreement on its Phase 3 trial design for pancreatic cancer, clearing the way to launch what would be the only immunotherapy registration trial currently planned for this notoriously difficult-to-treat disease.CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include:Pfizer (NYSE: PFE) announced positive results from Cohort 3 of the pivotal BREAKWATER trial evaluating BRAFTOVI in combination with cetuximab and FOLFIRI in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. The combination achieved a confirmed objective response rate of 64.4% compared to 39.2% with standard-of-care treatment, representing a statistically significant improvement."These data further strengthen the potential utility of BRAFTOVI for patients with BRAF V600E-mutant metastatic colorectal cancer. The significant improvement in response rates reflects the meaningful clinical benefit of this targeted combination therapy regimen for patients," said Jeff Legos, Chief Oncology Officer at Pfizer. "These results underscore the potential of BRAFTOVI as a standard of care for patients with this aggressive cancer."Among patients receiving the treatment regimen, 57.4% on BRAFTOVI plus cetuximab and FOLFIRI maintained response for six months or longer compared to 34.5% with standard therapy. Pfizer continues the BREAKWATER trial with an estimated completion in 2027.Verastem Oncology (NASDAQ: VSTM) announced it will discontinue its RAMP 203 Phase 1/2 trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) to focus resources on clinical development of VS-7375, an oral KRAS G12D inhibitor. The decision reflects the evolving treatment landscape as next-generation G12C inhibitors establish higher response rate benchmarks."RAMP 203 has provided important insights into treatment strategies and demonstrated proof-of-concept. While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates," said John Hayslip, Chief Medical Officer at Verastem Oncology. "Accordingly, we are prioritizing our clinical development of VS-7375, a potentially best-in-class oral KRAS G12D (ON/OFF) inhibitor, that demonstrated a 69% response rate in advanced KRAS G12D NSCLC."In the doublet combination arm, 30 G12C-inhibitor treatment-naïve patients achieved an overall response rate of 40% with a median progression-free survival of 11.1 months. Verastem Oncology continues advancing RAMP 205, evaluating avutometinib plus defactinib with chemotherapy in first-line metastatic pancreatic cancer.Perspective Therapeutics (NYSE-A: CATX) presented updated interim data from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-a-NET in patients with neuroendocrine tumors at the 2026 ASCO Gastrointestinal Cancers Symposium. The radiopharmaceutical demonstrated a 39% objective response rate in Cohort 2 patients regardless of SSTR2 expression profile, with 76% of patients remaining progression-free and alive."The updated interim results presented at ASCO-GI continue to support VMT-a-NET's compelling overall clinical profile at the 5 mCi dose," said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics. "With the robust clinical dataset being accrued from strong patient enrollment into our study, we believe we will be able to have meaningful engagement with regulatory agencies during 2026 on proceeding with VMT-a-NET into a registrational trial."The therapy continues to demonstrate favorable tolerability with no dose-limiting toxicities, treatment-related discontinuations, or clinically significant myelosuppression reported across 56 patients. Perspective Therapeutics has completed the Cohort 3 dose-limiting toxicity assessment and is cleared to enroll additional patients at the 6.0 mCi dose level.RenovoRx (NASDAQ: RNXT) announced continued commercial momentum with its RenovoCath FDA-cleared drug-delivery device now integrated at nine active U.S. cancer centers, up from five in September 2025. The company's TAMP therapy platform is designed to deliver chemotherapy near tumor sites, potentially enhancing effectiveness while minimizing systemic side effects associated with traditional intravenous administration."The growing adoption of RenovoCath by esteemed institutions like City of Hope Cancer Center and Moffitt Cancer Center, amongst others, is the driver of our commercial efforts and underscores the clinical need for more targeted oncology tools," said Shaun Bagai, CEO of RenovoRx. "We are encouraged by both the procedural feedback and the strong commercial interest we are seeing."The company generated approximately $900,000 in sales revenue through September 2025 and has strengthened its commercial team to drive growth in 2026. RenovoRx continues enrollment in its Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivery via RenovoCath for locally advanced pancreatic cancer.Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.precedenceresearch.com/oncology-markethttps://lumanity.com/perspectives/the-8-fda-regulatory-trends-shaping-2026-and-beyond/https://www.globenewswire.com/news-release/2025/12/02/3198196/0/en/Oncology-Market-Size-Worth-USD-668-26-Billion-by-2034.htmlhttps://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents Logo: https://mma.prnewswire.com/media/2838876/USA_News_Group_Logo.jpg





View original content to download multimedia:https://www.prnewswire.com/news-releases/668b-oncology-surge-5-platforms-cracking-the-code-on-gi-tumors-302675135.html

Original: $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

Very here....It just got brought up...$5 eh?... Something about December news?

haven't been on this board in a long time - basically because this one is off the worry list. once a company starts generating and growing revenue, it just becomes a game of "sit back and watch the quarterly up-trend in revenue growth".

The second thing that's positive is that we have institutional ownership - and those guys are buy & hold - no jumping in and out.

I'm not saying it won't still be volatile, but once the revenue starts rolling in (and growing) it's a whole new ball game - and we're in the game now. As for me, I won't even consider selling a share under $5 - but likely more like $10 before i consider.

RNXT......................................................................https://stockcharts.com/h-sc/ui?s=RNXT&p=W&b=5&g=0&id=p86431144783

RNXT, 10 day chart

$RNXT New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment

https://www.onclive.com/view/new-jersey-patients-receiving-first-of-its-kind-catheter-based-pancreatic-cancer-treatment

RNXT, under $2

Who does an offering before a spike in price? A company that know a spike is not coming... A company that needs to pay the bloated salaries..... A company ran by In*&a....

Under a dollar today? Once it does it will stay there until the reverse split. Bagai taking 800k a year out of this company a year is ridiculous ... that does not include shares he sells creatively. Why does he deserve all that money a year? What does he do for it? What about all the other clowns they are paying? Lol.. They will do most likely at 1 for 20 or so.... but with this new dilution to pay their salaries it might be bigger. Then it will sell down until one day they have a big spike that only they know about and then it will sell back down.. just like all the other biostock share selling companies out there. The spike wont help any current shareholder or new because 1 for 20 wipes those investors out. Run!

So I would say it's obvious they could not find a partner for the commercial side...lol.. who would. Why? You know why...

Think Shaun played hard ball and decided to go the offering (after lying about not needing one to see phase III out) and reverse split route to show them? Lol.. what does he care.. he get's free shares. Reverse split does not hurt the insiders... they just get more free shares. Wipes out all the investors they mislead. Why with all the positive talk and possible catalyst going forward does no one want any? This offering is a wipe out... will force under a dollar and reverse split. They are just following the how to script of selling stock.

lol.. .90 might see .50's tomorrow... soon comes the reverse split announcement. This was very shady even for Shaun..

after hours offering with no limits? Crazy... just following his script I guess.

YIKES... 1.08 DOWN DOWN .39 28% DOWN... HUGE OFFERING.. GOING UNDER A DOLLAR... GOING TO REVERSE SPLIT TO WIPE OUT ALL CURRENT SHAREHOLDERS.. THEN THEY WILL START ROLLING OUT THE MORE VAGUE PR'S AND KEEP THE $ TO THEMSELVES WITH NEW DUMB INVESTORS

LOL... I TOLD YOU ... NOW ANOTHER OFFERING WHEN THEY SAID THEY HAD ENOUGH MONEY TO GET TO PHASE III APPROVAL... THIS HAS NO AMOUNTS? LOL.. GOING UNDER A DOLLAR ACCORDING TO PLAN SO THEY CAN REVERSE SPLIT AND WIPE OUT CURRENT SHAREHOLDER... SO FUNNY... SO OBVIOUS

YIKES... PRE MARKET TRADE.. SELL AT 1.31
INTO THE 1.20'S TODAY.. MAYBE LOWER?
HEADING DOWN UNDER A DOLLAR WHERE THEY WILL REVERSE SPLIT TO WIPE OUT CURRENT SHAREHOLDERS AND BRING IN NEW WITH VAGUE PR'S... RUN!!!!!!

lol... I told you.. roll over has started.. 1.31 .... why all the selling with all the positive vague news being spread all over on this one? IT'S BECAUSE NO ONE BELIEVES THE VAGUE RIDICULOUSNESS.... NEED NEW SUCKERS AND THIS ONE IS AN OBVIOUS STAY AWAY FOR ANYONE WITH A BRAIN.

More vague repeated news this morning... no new takers.. insiders will be frustrated and dump this for what they can get...down to pennies... where it will reverse split to wipe out all the current shareholders and bring in new suckers for the new vague meaningless pr's to come.

This one is toast next week.... sold all day (two days in a row) 11 trades in last minute .. all sells.

No one is falling for their vague you no what any more. Will head to the pennies.. Reverse split coming... all current shareholders will be wiped out.

another day and another day of hitting the bid over and over... why? Cmon .... you know why... No new suckers on the vague fake hype... insiders have to get what they can... will sell all day... nothing will happen after hours... next week we head to pennies before the reverse split and start the process over again.

sold off all day!!! down .10 day ahead of the conference ...? Why? Insiders is my guess.. heading for a reverse split where they can pump it to bigger players... rinse and repeat.

Selling off this morning.. down .06 lots and lots of sells. Bad results coming? No follow up on the vague sales of their equipment... you guys were talking about leaks lately.... looks like something did leak and it's not good. oops down .08 now.

RNXT........................................https://stockcharts.com/h-sc/ui?s=RNXT&p=W&b=5&g=0&id=p86431144783

RNXT READY TO RUMBLE

RNXT....................https://stockcharts.com/h-sc/ui?s=RNXT&p=W&b=5&g=0&id=p86431144783

uh oh... looks like Shaun is up early too... saw the 1.50 bid.. 9 trades and 9000 shares later.. new bid 1.44 x 1.46
Heading you know where.... REVERSE SPLIT

Wow... 1.50 x 1.51 pre market.. already 986 shares traded...lol.. must be a big announcement coming... or the one I keep telling you about.. "1 for 20 reverse split to wipe out all current shareholders" except for the one guy that said reverse splits are good?

This one is getting a little scary... about to roll over... bigger block sells now (15,523 shares) bigger volume today with 80% sells. Will be under a dollar soon.. well under.. where it will reverse split and start the script over again. Ridiculous.

LOL... News this morning.. same old.... gonna present more vague information that no one cares about.. news = need to sell some shares..no one was biting this morning.. about 600 shares on the ask followed by 19 trades on the bid.

Ironically, lately the only stock that has been going up is $NVDA. Quite the conundrum you've put yourself in. Hey, I've left this place a few times, I get it.
You seem like a decent sort, but your word is all we can judge you on here.

but i stick to my word. In fact, if it's higher than even $100 by year end, i'll delete all of my accounts from every board. I'm sure some people will be thrilled with that :)

BTW, as far as penny stocks go, RNXT ain't the worst. It's actually trying to bust through resistance on increased trading volume. Which means, either someone is working a pump and dump, or this has a shot to go to $2.30 or so (currently $1.30). Almost worth the gamble....not for me, but for others I guess.

Today's news is a very bad sign for the company. Now they are trying to cover there butts for patent claims and procedures. The few years i owned this pos I was told by multiple people in the business that RNXT is not the only company do this procedure. Now they are trying to cell devices without the proper patents in place. This is the only reason for today's pr. Why else would they put this out today? Also phase III results are pushed out again? Why...lol... was going to be middle of 2024.. than 4th qtr of 2024. Then 1st qtr of 2025... now first half of 2025...lol This is a pos joke of a company who's business is selling shares... it is so thinly traded that they will finally give up and this will dump towards a quarter. Where it will reverse split and start the vague bs pumping all over again.

lol...I told you. The dump has started. Ask yourself this....if they presented yesterday and no one bought any only sells why? if they were going to make hundreds of millions selling there device and no one wants any only sells why? If phase III was so promising and no one wants any only sells why? ALL CURRENT SHAREHOLDERS OR ANYONE THAT BUYS SHARES BEFORE THEY REVERSE SPLIT WILL BE WIPED OUT ....THATS WHY!!!!! ONLY ONE'S THAT WILL MAKE MONEY ON THIS STOCK IS INSIDERS.... THEIR SHARES ARE FREE!

Looks like the one or two people who listened to all the vague bafoonery did not want any shares...lol..

Tomorrow could be a blood bath on the share price. They will give up soon.

Fireside chat with Shaun today at 4:30. More vague nonsense I will bet.. he needs to sell some shares.

Yikes.. not a good start.. not many trading days left this year.. thinly traded .. no one wants any.. insiders need to sell.. under a dollar by new year heading towards the reverse split that wipes out all current shareholders chances.

sell mode is on... no takers.. no new suckers.. this one is about to plummet

Lol... another pr about another location signing up for the trial... 45 minutes and only 217 shares bought....hahahahaha... no one cares or believes in this thinly traded scam.. soon they will give up and it will roll over... towards .50's

4 releases this morning on Etrade. They must need to dump some shares... 1 share traded.. no new suckers on this one.. they will have to dump soon.

Uh oh... new price target by some nobody analyst ... company must want to sell some shares.. so funny so obvious. These thinly traded non trusted companies need to try anything they can to sell shares. They will finally give up and the price will plummet to where it belongs...under .50 where they will reverse split and start the whole game over again.. wiping out all current shareholders.

You can buy some right now for 1.43 and be down .08 automatically ... sound good? Someone selling some share this morning... why? Because its going to be so great? Not for shareholders

RNXT READY TO RIP

WHAT DOES THE CHART TELL YOU? LOTS OF ROOM DOWN?

RNXT.....................................https://stockcharts.com/h-sc/ui?s=RNXT&p=W&b=5&g=0&id=p86431144783

ask yourself this question.... with all these bio stocks going up from 1-2.00 to 10-15.00 on way lesser (not as vague) news... why does no one want this one at a dollar? You know why... you can say it..

LOL.. more vague news about hundreds of millions in annual sales of some device.. with all that and a thinly traded (but lots of shares outstanding) stock nothing but a small buy and lots of sells.. it's ridiculous... they are trying to do anything they can to sell there shares without driving it to zero. Etrade made them put out a second pr right away saying this is all forward looking and vague. Soon they will give up and this will head towards zero and a massive reverse split.

This is ridiculous.. this site shows low of 1.15 etrade 1.15 yahoo 1.18
it traded 10k shares / sells at 1.10
more insider / market maker payoff crap... this will sell off way under a dollar then reverse split before any kind of bs run up... they need to wipe out current shareholders first so they don't sell for profits.

NVDA up to $140 today. You have 29 days left. Gonna miss you when you finally grasp all the realities of penny stock buying.

Ok.. so what does that chart tell you? It tells me that after the two biggest volume days it sold off huge... look at all those red bars ladder down...

What do you see?

RNXT.....................https://stockcharts.com/h-sc/ui?s=RNXT&p=W&b=5&g=0&id=p86431144783

The pumpers will be gone today... Bagai and buddies will continue to sell. Back down this fake pump goes...